Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. (June 2015)

• Record Type: Journal Article
• Authors: Swiecicki, Paul L.; Zhen, David B.; Mauermann, Michelle L.; Kyle, Robert A.; Zeldenrust, Steven R.; Grogan, Martha; Dispenzieri, Angela; Gertz, Morie A.
• Is Part Of: Amyloid. Volume 22:Number 2(2015:Jun.)
• Page Start: 123
• Page End: 131
• Publication Date: 2015-06
• Subjects: Amyloidosis -- Periodicals; 616.3995
• DOI: 10.3109/13506129.2015.1019610
• Languages: English
• ISSNs: 1350-6129

Abstract

<abstract> <title>Abstract</title> <p> <italic>Background</italic>: Hereditary transthyretin amyloidosis (ATTR amyloidosis) is a rare, clinically heterogeneous disease due to heritable mutations that lead to misfolding of a precursor protein and multisystem disease. This study sought to define the clinical characteristics, distribution of mutations and phenotypic presentation of patients presenting to our center with hereditary ATTR amyloidosis.</p> <p> <italic>Methods</italic>: With institutional review board approval, the study retrospectively identified patients who had hereditary ATTR amyloidosis and presented to Mayo Clinic in Rochester, Minnesota, from 1 January 1970, to 29 January 2013.</p> <p> <italic>Results</italic>: Of the 266 patients with the diagnosis of hereditary ATTR amyloidosis, a pathogenic mutation was identified in 206; the most common mutation was Thr60Ala (68 patients [25%]). Median age at diagnosis was 63.3 years; median survival after diagnosis was 56.8 months (10th–90th percentile, 16.0–297.9). On multivariate analysis, age at diagnosis (risk ratio, 15.65; <italic>p</italic> < 0.0001), Thr60Ala mutation (risk ratio, 1.52; <italic>p</italic> = 0.04), Val122Ile mutation (risk ratio, 2.83; <italic>p</italic> = 0.003), peripheral neuropathy (risk ratio, 1.69; <italic>p</italic> = 0.013) and weight loss (risk ratio, 1.81; <italic>p</italic> = 0.002) were risk factors for death.</p> <p> <italic>Conclusion</italic>: Our data characterize the features of hereditary ATTR amyloidosis in a large cohort, demonstrate the heterogeneity among mutations and support the need to better characterize the clinical progression of individual mutations.</p> </abstract>